139 related articles for article (PubMed ID: 25610736)
1. Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.
Zom GG; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Oncoimmunology; 2014; 3(7):e947892. PubMed ID: 25610736
[TBL] [Abstract][Full Text] [Related]
2. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
3. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
[TBL] [Abstract][Full Text] [Related]
4. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
6. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.
Khan S; Bijker MS; Weterings JJ; Tanke HJ; Adema GJ; van Hall T; Drijfhout JW; Melief CJ; Overkleeft HS; van der Marel GA; Filippov DV; van der Burg SH; Ossendorp F
J Biol Chem; 2007 Jul; 282(29):21145-59. PubMed ID: 17462991
[TBL] [Abstract][Full Text] [Related]
7. Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells.
Zom GG; Willems MMJHP; Meeuwenoord NJ; Reintjens NRM; Tondini E; Khan S; Overkleeft HS; van der Marel GA; Codee JDC; Ossendorp F; Filippov DV
Bioconjug Chem; 2019 Apr; 30(4):1150-1161. PubMed ID: 30865430
[TBL] [Abstract][Full Text] [Related]
8. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
11. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
12. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
[TBL] [Abstract][Full Text] [Related]
13. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design.
Wada H; Shimizu A; Osada T; Tanaka Y; Fukaya S; Sasaki E
PLoS One; 2018; 13(7):e0199249. PubMed ID: 29969453
[TBL] [Abstract][Full Text] [Related]
15. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG; Wiesmüller KH; Chandran PA; Zelba H; Rusch E; Gouttefangeas C; Kowalewski DJ; Di Marco M; Haen SP; Walz JS; Gloria YC; Bödder J; Schertel JM; Tunger A; Müller L; Kießler M; Wehner R; Schmitz M; Jakobi M; Schneiderhan-Marra N; Klein R; Laske K; Artzner K; Backert L; Schuster H; Schwenck J; Weber ANR; Pichler BJ; Kneilling M; la Fougère C; Forchhammer S; Metzler G; Bauer J; Weide B; Schippert W; Stevanović S; Löffler MW
J Immunother Cancer; 2019 Nov; 7(1):307. PubMed ID: 31730025
[TBL] [Abstract][Full Text] [Related]
16. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
17. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
19. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
